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Augmentation of antioxidant defenses may help protect tissues against 
ischemia-reperfusion i jury associated with operations involving cardio- 
pulmonary bypass. In this study we examined the effect of pretreating 
patients with a-tocopherol (vitamin E) and ascorbic acid (vitamin C) or 
placebo on injury to the myocardium. Seventy-six subjects undergoing 
elective coronary artery bypass grafting participated in a prospective, 
double-blind, placebo-controlled randomized trial, receiving either placebo 
or both 750 IU dl-a-tocopherol per day for 7 to 10 days and 1 gm ascorbic 
acid 12 hours before the operation. Plasma o~-tocopherol concentrations, 
raised fourfold by supplementation, fell by 70% after the operation in the 
supplemented group and to negligible levels in the placebo group. There 
were no significant differences between the groups with respect o release of 
creatine kinase MB isoenzyme over 72 hours, nor in the reduction of the 
myocardial perfusion defect determined by thallium 201 uptake. Electro- 
cardiography provided no evidence of a benefit from antioxidant supple- 
mentation. Thus the supplementation regimen prevented the depletion of 
the primary lipid soluble antioxidant in plasma, but provided no measur- 
able reduction in myocardial injury after the operation. (J Thorac Cardio- 
vasc Surg 1997;113:942-8) 
C ardiac surgery with cardiopulmonary bypass (CPB) is associated with the risk of ischemia- 
reperfusion type injury to the myocardium and other 
tissues, as a result of aortic crossclamping and 
altered arterial blood flow patterns. Tissue injury 
may arise during both the period of ischemia nd 
the initial seconds of reperfusion. 1 In terms of the 
free radical hypothesis, reperfusion injury results 
from the production of oxygen-derived free radicals 
and other reactive oxygen substances in amounts 
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that overwhelm the body's endogenous antioxidant 
defenses. The whole-body inflammatory reaction 
resulting from CPB contributes to the oxidative 
stress. Complement-activated n utrophils are a ma- 
jor source of oxidant species 1'2 and are implicated in 
microvascular injury and consequent parenchymal 
organ injury. 1' 3 
Evidence for myocardial reperfusion injury in- 
duced by oxygen-derived free radicals has been 
largely derived from animal models and in vitro 
perfused hearts; studies in human beings are lim- 
ited. 4-a Recently, it has been reported that myocar- 
dial reperfusion after aortic crossclamping in human 
beings leads to increases in markers of free radical 
activity, such as lipid peroxidation, TM and a de- 
crease in myocardial concentrations of the major 
membrane antioxidant o~-tocopherol. 12 Studies show- 
ing a protective ffect of allopurinol, an inhibitor of 
xanthine oxidase (which catalyzes th  production of 
superoxide radicals) during coronary artery bypass 
grafting (CABG) are consistent with the notion of 
oxidative stress during reoxygenation. 6' 13, 14 
There are a number of theoretic approaches to 
limiting the toxic effects of oxygen-derived free 
radicals in vivo) One is to augment he body's 
antioxidant defenses before surgery. 15 The primary 
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physiologic antioxidants are the lipid-soluble, chain- 
breaking vitamin a-tocopherol  (vitamin E) and, in 
the aqueous phase, ascorbic acid (vitamin C) and 
glutathione. 16 Initial studies suggest that pretreat- 
ment of patients undergoing CPB with c~-tocopherol 
or ascorbic acid reduces lipid peroxidation (malon- 
dialdehyde production) and myocardial  tissue injury 
(enzyme etttux) during CPB. s' 9, 17, 18 However,  the 
potential  benefit of  antioxidant administration, and 
especially of a-tocopherol ,  on ischemia-reperfusion 
injury in vivo is controversial. 
The present study was undertaken to determine 
the effect of pretreating patients undergoing CPB 
with both o~-tocopherol and ascorbic acid or placebo 
on markers of myocardial  injury after CPB. Inas- 
much as c~-tocopherol is relatively poorly absorbed, 
dietary supplementat ion was extended to 7 to 10 
days before the operat ion to augment both its 
circulating and tissue concentrations, s' 19 Ascorbic 
acid, on the other hand, is readily absorbed and 
distributed to tissues. Because ascorbic acid may be 
involved in the regenerat ion of o~-tocopherol f rom 
its o~-tocopheroxyl radical, 2° supplementat ion with 
both antioxidants was u ed to maximize antioxidant 
protection after CPB. 
Methods 
Patients. Patients undergoing CABG were admitted to 
the trial if the following criteria were met: he patient was 
aged 18 to 75 years, did not smoke, and gave informed 
consent more than 10 days before the operation. Patients 
were excluded if they were receiving coumarin derivatives 
(very high doses of vitamin E may potentiate anti-vitamin 
K therapy), vitamin supplements, or corticosteroids. In 
addition, malabsorption syndromesl severe asthma, ob- 
structive pulmonary disease, poor left ventricular function 
(ejection fraction < 40%), and a history of alcoholism, 
drug abuse, psychosis, or a combination of these condi- 
tions excluded patients from the study. Eligible patients 
were then assigned the next available (randomized) study 
number and accompanying coded treatment. 
Seventy-nine patients were enrolled. Three subjects 
were excluded after randomization because of canceled 
operations (urgent cases took priority over scheduled 
operations); thus the study finally consisted of 76 patients. 
Thirty-eight patients were assigned to the vitamin-supple- 
mented (active) group and the same number to the 
placebo group. The mean age was 59.9 years; 63 of 76 
(82.9%) were male (Table I). 
The study was conducted in accordance with the ethical 
guidelines of the National Health and Medical Research 
Council of Australia; the protocol was approved by the 
Human Ethics Committee of The Prince Charles Hospi- 
tal, Brisbane. 
Intervention (supplementation). Enrolled subjects re- 
ceived a 10-day supply of capsules (active or placebo) for 
Table I. Clinical characteristics of patients 
Parameter Placebo Supplemented Combined 
Age (mean _+ SD; yr) 59.7 _+ 7.7 60.0 + 7,0 59.9 _+ 7.3 
Sex ratio (male/femaIe) 30:8 33:5 63:13 
Bypass time (median, 68.0 74.0 70.5 
first quartile, third 
quartile; rain) 50.8, 90.0 56.8, 107.0 55.0, 90.0 
Crossclamp time (medi- 41.0 44.0 43.0 
an, first quartile, third 
quartile; min) 29.5, 55.0 30.8, 55.3 30.0, 55.0 
No. of grafts (1/2/3/4/5/6) 1/5/11/10/8/1 0/2/12/12/9/2 1/7/23/22/17/3 
SD, Standard eviation. 
self-administration. The active capsules provided 750 IU 
dl-c~-tocopheryl acetate daily; the placebo provided an 
equivalent amount of sucrose. Compliance was monitored 
by measuring serum a-tocopherol levels and by capsule 
counts. Twelve hours before the operation, supplemented 
patients also received 1 gm ascorbic acid orally, and 
control subjects received a placebo (1 gm sucrose). No 
side effects attributable to the supplement or placebo were 
reported. 
Surgical procedure. Patients underwent CABG with 
standard CPB. In brief, after systemic heparinization, 
CPB was established with Cobe roller pumps (Cobe 
Laboratories, Inc., Denver, Colo.), a flat-sheet membrane 
oxygenator (Cobe) and an arterial filter (Pall Biomedical 
Products, East Hills, N.Y.). The extracorporeal circuit was 
primed with 2 L of crystalloid solution (lactated Ringer's 
solution); packed cells were included if the diluted hemat- 
ocrit value was expected to fall below 0.20. Minimum flow 
rates of 2.4 L/min per square meter and core temperatures 
of 30 ° to 32 ° C were maintained throughout CPB. Multi- 
dose hypothermic potassium cardioplegic solution and topi- 
cal hypothermia were used during aortic rossclamping. 
Median CPB and crossclamp times are shown in Table I. 
Sample collection. Peripheral venous blood was col- 
lected before the operation and at intervals over the 
subsequent 72 hours. 
Laboratory methods. Plasma creatine kinase isoen- 
zyme MB (CK-MB) was estimated by electrophoresis by 
means of the REP CK-8 isoenzyme system (Helena 
Laboratories, Beaumont, Tex.). Plasma c~-tocopherol was 
estimated by ultraviolet detection at 285 nm after separa- 
tion by high-performance liquid chromatography. 21 c~-To, 
copherol acetate served as an internal standard. Because 
fluid balance is largely restored by 12 hours and because 
our primary concern was the comparison between patient 
groups, plasma enzyme and vitamin levels were not cor- 
rected for the effect of the crystalloid pump prime. 
Electrocardiography. Electrocardiograms were ob- 
tained before the operation and at hospital discharge 
(usually the sixth or seventh day). A 54-criteria QRS 
scoring system a2 was used to evaluate the extent of 
myocardial damage. The theoretic maximal score on this 
system is 32 points, with each additional point represent- 
ing a loss of approximately 3% of left ventricular myocar- 
dium. Measurements were made on standard 12-lead 
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Fig. i. Changes in plasma c~-tocopherol concentrations 
after cardiac surgery (medians and first and third quar- 
tiles). The open circles indicate patients receiving supple- 
mental c~-tocopherol and ascorbic acid, and the solid 
symbols, the placebo group. The difference between 
groups, changes with time, and group × time interaction 
were all highly significant (p < 0.001). 
electrocardiograms recorded at a frequency response of 
0.05 to 100 Hz using manual callipers. 
Thallium scans. The extent of perioperative segmental 
myocardial injury was assessed by single-photon emission 
computed tomographic (SPECT) thallium 201 (T1-201) 
scans obtained at rest in the preoperative period and 
before hospital discharge. Patients underwent the scan if 
they gave written, informed consent and if the scan could 
be scheduled uring the work week (n = 41). Subjects 
were given an intravenous injection of 80 MBq of T1-201 
at rest after an overnight fast. Within 30 minutes of 
injection, a SPECT scan was acquired in 32 angles over 
180 degrees (right anterior oblique to left posterior 
oblique). Tomograms were reconstructed byfiltered back- 
projection, with oblique-angle reorientation along the 
long axis of the left ventricle, and displayed in oblique 
short-axis and horizontal and vertical long-axis slices. 
Preoperative and postoperative scan pairs for each patient 
were compared in the same format as conventional stress/ 
rest T1-201 scan pairs, with quantitation of myocardial 
thallium distribution using a two-dimensional polar 
map. 23 Scans were interpreted by an experienced nuclear 
medicine physician who was blinded to the patient's 
treatment. 
Total defect extent was estimated from the polar map 
analysis, as the percentage of total left ventricular volume 
in which T1-201 uptake (relative to maximal uptake) was 
more than 2.5 standard eviations below the mean of a 
gender-specific reference database of resting myocardial 
T1-201 distribution. Defect severity on the tomographic 
slices was graded for each of five segments (anterior, 
septal, inferior, lateral, and apical) using a semiquantita- 
tive color table, as follows: 0 = normal; 1 = mild ([> 80% 
of maximal uptake])/questionable defect/probable arti- 
fact; 2 = definite defect (50% to 80% of maximal uptake); 
3 = severe (< 50% of maximal uptake). The total score 
for all five segments was used as a global severity score. In 
addition, a combined (severity × extent) score was deter- 
mined. 
Statistics. The present trial of preoperative supple- 
mentation with antioxidant vitamins in cardiac surgery 
involved a renal as well as a cardiac arm; the renal 
substudy will be reported elsewhere. Sample size determi- 
nations and the power calculations were based on renal 
outcomes. On the basis of log transformed data from the 
placebo group (n = 38), retrospective power calculations 
showed that a 75% change in the logged CK-MB area 
under the curve would be detected with power = 80% and 
= 0.05 (two-tailed). As a result of substantial skewness 
of the distributions, values are reported as medians (first 
quartile, third quartile). Pre-post differences were approx- 
imately normally distributed, and consequently differ- 
ences between the patient groups' time-related ata were 
analyzed by parametric paired t tests or two-way repeated- 
measures analysis of variance, with the use of SPSS-PC+ 
version 4.0 (SPSS, Inc., Chicago, Ill.). A square root 
transformation was applied to CK-MB time profiles, QRS 
scores, and to c~-tocopherol values because of unequal 
variances across the groups. For the calculation of the 
areas under the CK-MB plasma concentration curves, 
Sigmaplot graphic software (Jandel) was used, with the 
trapezoidal rule used for unequally spaced x values. 
The significance of differences between two data sets 
was determined by Student's t test or the Mann-Whitney 
rank sum test for parametric and nonparametric data, 
respectively. Correlations between variables were sought 
with the use of the Pearson product moment correlation. 
Ap  value < 0.05 was considered significant. 
Results 
There were no differences between the study 
groups with respect o duration of bypass (p = 0.37) 
and total crossclamp times (p = 0.60). There was no 
significant difference in the proport ion of patients 
with crossclamp times greater than 50 minutes (0.36 
in the supplemented group; 0.30 in the placebo 
group; p = 0.75). One patient required surgical 
d6bridement and rewiring for sternal infection, and 
another was reintubated and the lungs were venti- 
lated on day 5. One patient did not regain conscious- 
ness and died after the study period. 
Plasma a-tocopherol concentrations (Fig. 1). 
Preoperative plasma a-tocopherol  concentrations 
were fourfold higher in the supplemented group 
(medians 44.7 vs 11.4 rag/L, p < 0.001). Postopera- 
tively, median concentrations in the supplemented 
group fell by 70% but remained at or above normal 
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Fig. 2. Changes in plasma CK-MB concentrations after cardiac surgery 'medians and first and third 
quartiles). Laboratory normal reference range, 0 to 10 U/L. The changes with time were highly significant 
(p < 0.001); group × time interaction, p = 0.47; difference between groups, p = 0.71. 
Table II. CK-MB release after cardiac operations 
Placebo group (n = 36) Supplemented group O~ = 37) 
Parameter Median First, third quartile Median First, third quartile p Value 
CK-MB peak (U/L) 29 16, 53 28 17, 43 0.81 
Area under curve (U • hr/L) 622 333, 793 476 299, 902 0.56 
levels. In contrast, concentrations in the placebo 
group decreased from normal to negligible levels 
within 3 hours of the operation. The difference 
between groups, changes with time, and group × 
time interaction were all highly significant (p < 
0.001). 
Plasma creatine kinase isoenzymes (Table II and 
Fig. 2). Changes in plasma CK-MB concentrations 
with time were highly significant (p < 0.001). Me- 
dian peak values reached were 29 and 28 U/L in the 
placebo and supplemented subjects, respectively 
(p = 0.81). There were no significant differences 
between the groups with respect o CK-MB profiles 
(p = 0.71) nor with respect o CK-MB areas under 
the curve (p = 0.56). The median of the placebo 
group (622 U.hr /L) ,  however, was 23.5% higher 
than in the supplemented group (476 U .  hr/L). The 
power of the performed test was, however, low 
(0.37), suggesting that this negative finding be inter- 
preted with caution. 
There was no correlation between preoperative 
plasma c~-tocopherol levels and the CK-MB area 
under the curve for the two patient groups consid- 
ered either separately or collectively or when the 
combined ata were log-transformed (rrl < 0.1,p > 
0.7). 
Electrocardiography (Table III). Adequate paired 
preoperative and postoperative lectrocardiograms 
were available in 49 patients (23 placebo, 26 active 
treatment). Reasons for exclusion from the electrocar- 
diographic analysis included the presence of bundle 
branch block (n = 12) or left ventricular hypertrophy 
(n = 1), inadequate t chnical quality for analysis (n = 
8), or death (n = 1). 
The active treatment group bad significantly 
worse QRS scores than the placebo group at base- 
line (p = 0.03), presumably as a result of chance. 
Postoperative QRS scores were worse than preop- 
erative scores in the combined group (p = 0.001), 
although the interaction between group and time 
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Table IlL Extent of myocardial injury determined 
by QRS score (units) 
Placebo group Supplemented group 
(n =23) (n =26) 
First, First, 
Median third quartile Median third quartile 
Preoperative 0 0, 1 1 0, 3 
Postoperative 1 0, 2 4 1, 8 
Change 0 0, 2 0 0, 3 
Between-group comparison: p = 0.008; changes with time: p = 0.001; 
group × time interaction: p = 0.92. 
was not statistically significant (p = 0.92). There was 
no difference between the two groups with respect 
to the proportion of subjects with new Q waves after 
the operation (0.33 and 0.36 for placebo and sup- 
plemented groups, respectively; p = 0.92). 
Thallium scans (Table IV). There were no sig- 
nificant differences between the groups before the 
operation or at the time of discharge with respect to 
either the severity or the extent of perfusion defects 
at rest or for the combined (severity × extent) score. 
As expected, a significant improvement in all these 
parameters was noted after CABG (p -< 0.002). 
Discussion 
As the primary hydrophobic, hain-breaking anti- 
oxidant, o~-tocopherol has attracted interest as an 
agent for limiting ischemia-reperfusion njury result- 
ing from oxygen-derived free radicals. 8'n'12'17 
Studies of a-tocopherol treatment (frequently com- 
bined with ascorbic acid) in isolated perfused animal 
hearts have consistently shown less functional, struc- 
tural, and biochemical changes than in controls. 24-26 
In human studies, plasma and myocardial a-tocoph- 
erol levels have been shown in some s' 11, 12, 17 but 
not all studies 7 to decrease during bypass. This fall 
may be prevented by supplementation. 17 Supple- 
mentation also attenuated the rise in levels of 
plasma hydrogen peroxide (H202)  17 and  the lipid 
peroxidation marker malondialdehyde during and 
immediately after CPB. 9 Whether these effects were 
clinically significant was addressed in the present 
study, which showed that augmentation of patients' 
antioxidant reserves by supplementation with a-to- 
copherol and ascorbic acid had no significant effect 
on markers of myocardial injury after uncompli- 
cated CPB operations. The lower median for 
CK-MB area under the curve in the treated group, 
although not statistically significant, is of a magni- 
tude (23.5%) to suggest a possible clinical effect in 
some patients. 
The lack of a demonstrable protective ffect in the 
present study cannot be attributed to low concen- 
trations of oz-tocopherol. Although plasma levels 
and not tissue levels were measured, it is probable 
that the latter was raised albeit to a lesser degree. 8 
After surgery, plasma concentrations of a-tocoph- 
erol fell by 70% in the supplemented group, but 
concentrations remained at or above normal levels 
(see Fig. 1). In contrast, concentrations in the 
placebo group fell to negligible levels within 3 hours 
of the operation. Although part of this decrease may 
be attributed to hemodilution, the observed changes 
far exceeded the effects of hemodilution. Part of the 
change may also be attributed to changes in plasma 
lipids. Because the bulk of the a-tocopherol is 
carried by plasma lipoproteins, levels of the vitamin 
are highly correlated with total plasma lipid levels, 7
which tend to fall in the postoperative period. 
Nevertheless, the data indicate a clear difference 
between the groups in the circulating levels of 
a-tocopherol after surgery. 
Studies in isolated perfused animal hearts 24-26 
suggest that the fall in antioxidant reserve may have 
exposed some patients to the risk of clinically signif- 
icant myocyte injury in the postoperative period. 
CK-MB profiles were fairly similar in supplemented 
and placebo groups; however, the power of the 
performed test for CK-MB area under the curve 
(normalized ata) was low (0.37), suggesting that 
the negative finding be interpreted with caution. It is 
therefore not possible to exclude a clinically signif- 
icant benefit with certainty. The 23.5% lower me- 
dian for CK-MB area under the curve in the sup- 
plemented group is suggestive of a clinically 
significant effect, although changes of less than 25% 
are unlikely to be of major functional or prognostic 
significance. It is possible that a larger clinical trial 
may detect a clinically and statistically significant 
effect. Earlier studies are not helpful in this respect. 
On the basis of their study of 18 patients, Ballmer 
and associates 7 concluded that c~-tocopherol (and 
carotenoid) concentrations were of no major con- 
cern during and after cardiac operations. In another 
recent study involving use of a-tocopherol supple- 
mentation or placebo in 28 patients with cardiac 
disease, Yau and colleagues s showed small but 
significant improvements in myocardial metabolism, 
ventricular function, and CK-MB release but con- 
cluded that these changes were not clinically signif- 
icant for low-risk patients. 
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Table IV. Extent and severity of cardiac defect before and after cardiac surgery asdetermined by Tl-201 scans 
Placebo group (n = 18) Supplemented group (n - 23) 
Parameter Median First, third quartile Median First, third quartile 
Extent (%)* 
Pre 14.0 2, 28 18.0 7, 40 
Post 4.5 4, 14 3.0 1, 29 
Severity (score)t 
Pre 3.0 1, 6 3.0 2, 10 
Post 1.0 0, 3 2.0 1, 7 
Severity × extent (score):~ 
Pre 28.0 4, 190 36.0 16, 420 
Post 9.0 0, 34 9.0 1,273 
*Between-group comparison: p - 0.45; changes with time (pre-post): p = 0.001; 
1"Between group comparison: p = 0.09; changes with time (we-post): p = 0.001; 
:~Between group comparison: p - 0.12; changes with time (pre-post): p = 0.002; 
group × time interaction: p 0.98. 
group × time interaction: p = 0.22. 
group X time interaction: p - 0.45. 
A note of caution may be added here. None of the 
patients in the present study had low levels of 
a-tocopherol in the preoperative period; it is possi- 
ble that preoperative deficiency of the antioxidant 
may have yielded different results. Second, the 
present group of patients undergoing CABG were 
subjected to relatively short periods of ischemia 
(median crossclamp time 43 minutes). Prolonged 
ischemic periods are more likely to be associated 
with oxidative stressY Third, although CK-MB is 
the traditional gold standard for the diagnosis of 
myocardial infarction, peak values may be mislead- 
ing after cardiac surgery. 28 We therefore combined 
CK-MB measurements with other myocardial indi- 
cators (electrocardiograms and T1-201 scans). It is 
possible that the latter investigations may not have 
found significant group differences, because they are 
not sensitive indicators of perioperative free radical 
injury. They have also not been specifically validated 
in a cardiac surgical population. Interpretation of 
the QRS scoring was complicated by the baseline 
imbalance between the treatment and placebo 
groups, with the treatment group having more ex- 
tensive damage before surgery. However, QRS 
scores increased by a similar extent in both the 
placebo and treatment groups, with no suggestion of 
a benefit from antioxidant supplementation. 
The efficacy of high-dose ascorbic acid adminis- 
tration on myocardial reperfusion injury in human 
beings has been recently reported. Intravenous 
ascorbic acid (1 gm) 90 minutes before bypass 
followed by cardioplegic solutions containing ascor- 
bic acid (1 retool/L) significantly reduced the release 
of cardiac enzymes in patients with ischemic periods 
greater than 50 minutes. 29 High doses of ascorbic 
acid (250 mg/kg) given intravenously before CPB 
and at aortic crossclamping significantly reduced 
serum malondialdehyde, CK-MB, and lactate dehy- 
drogenase concentrations in the postoperative p ri- 
od. 18 Cardiac output was significantly higher in the 
treated patients for the first 6 hours after the 
operation. 18 These two studies uggest hat high 
doses of ascorbic acid may effectively scavenge free 
radicals during and after CPB and offer a measure 
of protection to the myocardium. No statistically 
significant effects were seen in the present rial, in 
which an effectively lower dose was used (1 gm 
orally 12 hours before the operation). 
The lack of obvious benefit from antioxidant 
pretreatment in the present study is disappointing in
the light of numerous animal studies that support 
the concept of ischemia-reperfusion injury amena- 
ble to protection by antioxidants. 24-26 Whether this 
is due to species differences, differences in treatment 
regimens, or periods of induced ischemia is uncer- 
tain. In human studies, administration of drugs with 
known antioxidant activity may be confounding. 
Allopurinol,/3-blockers, and calcium channel block- 
ers (which were commonly administered before 
surgery) may independently contribute to the free 
radical scavenging defenses of the patients. 8'10, 13 
Concomitant medications were similar in the patient 
groups, and drug-related effects are therefore un- 
likely to be a confounding factor in the present 
study. 
In summary, extended supplementation with o~-to- 
copherol combined with ascorbic acid 12 hours 
before routine, uncomplicated cardiac surgery pre- 
vented the depletion of the primary lipid-soluble 
antioxidant a-tocopherol inplasma, but provided no 
additional protection to the myocardium over the 
standard surgical regimen. Further studies are re- 
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qui red to determine  the possible benef i t  for pat ients  
with longer  crossc lamp t imes who are at greater  risk 
of  i schemia- reper fus ion  injury. 
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